MADAM-6

MADAM-6
Clinical data
Other names	6-Methyl-MDMA; 2,N-Dimethyl-4,5-methylenedioxyamphetamine
Routes of; administration	Oral
ATC code	None;
Pharmacokinetic data
Duration of action	Unknown
Identifiers
	IUPAC name N-methyl-1-(6-methyl-2H-1,3-benzodioxol-5-yl)propan-2-amine;
CAS Number	207740-46-3;
PubChem CID	44719578;
ChemSpider	21106340;
UNII	W3H6GHJ73C;
CompTox Dashboard (EPA)	DTXSID80660368 ;
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1(=CC2=C(C=C1CC(C)NC)OCO2)C;
	InChI InChI=1S/C12H17NO2/c1-8-4-11-12(15-7-14-11)6-10(8)5-9(2)13-3/h4,6,9,13H,5,7H2,1-3H3; Key:CRQPDNIUPWXPNK-UHFFFAOYSA-N;

MADAM-6, or 2,N-dimethyl-4,5-methylenedioxyamphetamine or as 6-methyl-MDMA, is a drug of the phenethylamine, amphetamine, and MDxx families, similar in structure to MDMA (ecstasy).^[2] MADAM-6 was first synthesized by Alexander Shulgin.^[1] In Shulgin's book PiHKAL, the minimum dosage is listed as greater than 280 mg, and the duration is unknown.^[1] MADAM-6 produces few to no effects and Shulgin describes it as "not active".^[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MADAM-6.

MADAM-6 has been studied for its potential antiparkinsonian effects.^[3] However, no clinical trials suggest the drug is effective against Parkinson's disease.

References

^ ^a ^b ^c ^d ^e MADAM-6 entry in PiHKAL
^ Patt M, Gündisch D, Wüllner U, Blocher A, Kovar KA, Machulla HJ (1999). "N-[11C]methyl-3,4-methylenedioxyamphetamine (Ecstasy) and 2-methyl-N-[11C]methyl-4,5-methylenedioxyamphetamine: Synthesis and biodistribution studies". Journal of Radioanalytical and Nuclear Chemistry. 240 (2): 535–540. doi:10.1007/BF02349410. S2CID 96272983.
^ US patent 2015025063, Caron MG, Sotnikova TD, Gainetdinov RR, "Antiparkinsonian Action Of Phenylisopropylamines", published 2014-09-30, issued 2015-01-22, assigned to Duke University

[PiHKAL-1] MADAM-6 entry in PiHKAL

[2] Patt M, Gündisch D, Wüllner U, Blocher A, Kovar KA, Machulla HJ (1999). "N-[11C]methyl-3,4-methylenedioxyamphetamine (Ecstasy) and 2-methyl-N-[11C]methyl-4,5-methylenedioxyamphetamine: Synthesis and biodistribution studies". Journal of Radioanalytical and Nuclear Chemistry. 240 (2): 535–540. doi:10.1007/BF02349410. S2CID 96272983.

[US2015025063-3] US patent 2015025063, Caron MG, Sotnikova TD, Gainetdinov RR, "Antiparkinsonian Action Of Phenylisopropylamines", published 2014-09-30, issued 2015-01-22, assigned to Duke University

[1]

[2]

[3]

See also

References